This CRISPR-induced repression attenuated tumor cell proliferation and was valuable in defining the potential role of chromodomain helicase DNA binding protein 2 (CHD2) and Protein Tyrosine Phosphatase Receptor Type Z1 (PTPRZ1) as novel targets for molecular therapy to treat meningioma patients. This evidence concerns the gene CHD2 and meningioma.